1. Home
  2. EOD vs FHTX Comparison

EOD vs FHTX Comparison

Compare EOD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Global Dividend Opportunity Fund of Beneficial Interest

EOD

Allspring Global Dividend Opportunity Fund of Beneficial Interest

HOLD

Current Price

$6.51

Market Cap

271.7M

Sector

Finance

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.29

Market Cap

323.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOD
FHTX
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.7M
323.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EOD
FHTX
Price
$6.51
$4.29
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.50
AVG Volume (30 Days)
87.1K
129.0K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
9.28%
N/A
EPS Growth
N/A
25.32
EPS
N/A
N/A
Revenue
N/A
$30,909,000.00
Revenue This Year
N/A
$8.89
Revenue Next Year
N/A
$20.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.75
52 Week Low
$5.14
$3.27
52 Week High
$6.59
$6.95

Technical Indicators

Market Signals
Indicator
EOD
FHTX
Relative Strength Index (RSI) 58.80 46.02
Support Level $5.58 $3.65
Resistance Level $6.59 $5.82
Average True Range (ATR) 0.10 0.27
MACD -0.01 0.02
Stochastic Oscillator 60.93 58.87

Price Performance

Historical Comparison
EOD
FHTX

About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest

Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Share on Social Networks: